Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926263 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00926263 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 28 participants.
The verdict
NCT00926263, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.
Interventions
- BIOLOGICAL CP-751,871
- BIOLOGICAL CP-751,871, moxifloxacin, saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926263
The ClinicalTrials.gov registry entry for NCT00926263 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CP-751,871 is the first listed.
NCT00926263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926263 about?
NCT00926263 is a clinical study titled "A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects". This study is primarily to evaluate the single dose pharmacokinetics of CP-751,871 and its effect on QT interval prolongation.
What is the current status of trial NCT00926263?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00926263?
The interventions under investigation include: CP-751,871 (BIOLOGICAL), CP-751,871, moxifloxacin, saline (BIOLOGICAL).
Who is sponsoring clinical trial NCT00926263?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.